CCP
TRIB

Centaur Capital Partners’s Trinity Biotech TRIB Stock Holding History

Centaur Capital Partners’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-517
Closed -$887K – 26
2015
Q3 		$887K Sell
517
-283
-35% -$683K 1.33% 28
2015
Q2 		$2.17M Sell
800
-100
-11% -$260K 3.7% 13
2015
Q1 		$2.6M Hold
900
– – 3.61% 11
2014
Q4 		$2.36M Buy
+900
New +$2.33M 3.81% 12

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Centaur Capital Partners's TRIB Position: Q4 2015 in Review

Centaur Capital Partners sold out of Trinity Biotech (TRIB) in Q4 2015, closing a stake of 517 shares — an estimated $887K sold.

Centaur Capital Partners first reported a position in TRIB in Q4 2014 and held it in 4 quarters. The position peaked at $2.6M in Q1 2015. 81 funds tracked by Wall St. Rank hold TRIB as of Q4 2015.

  • Centaur Capital Partners reported no remaining Trinity Biotech position as of Q4 2015 after selling out during the quarter.
  • Centaur Capital Partners sold 517 Trinity Biotech shares in Q4 2015, an estimated $887K.
  • Centaur Capital Partners first reported a position in Trinity Biotech in Q4 2014 and held it in 4 quarters.
  • Centaur Capital Partners's Trinity Biotech position peaked at $2.6M in Q1 2015.
  • 81 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2015.

Based on Centaur Capital Partners's 13F filing for Q4 2015, filed 16 Feb 2016.